| NCT07149415 | A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55 | RECRUITING | PHASE1 | 2025-09-02 | 2025-10-16 | 2025-10-16 |
| NCT07133828 | A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old | RECRUITING | PHASE1 | 2025-08-29 | 2026-08-06 | 2026-08-06 |
| NCT07019064 | A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55 | COMPLETED | PHASE1 | 2025-06-11 | 2025-08-19 | 2025-08-19 |
| NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | RECRUITING | PHASE3 | 2025-06-09 | 2029-11-22 | 2027-11-16 |
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | RECRUITING | PHASE3 | 2025-05-22 | 2029-03-29 | 2028-12-29 |
| NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | RECRUITING | PHASE3 | 2025-05-08 | 2029-06-05 | 2027-05-31 |
| NCT06454721 | A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults | RECRUITING | PHASE1 | 2025-01-30 | 2026-07-30 | 2026-02-16 |
| NCT06555419 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | RECRUITING | PHASE1 | 2025-01-16 | 2026-05-15 | 2026-05-15 |
| NCT06741657 | A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways | RECRUITING | PHASE1 | 2025-01-02 | 2026-04-08 | 2026-04-08 |
| NCT06685757 | A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR) | RECRUITING | PHASE3 | 2024-12-03 | 2027-06-01 | 2026-12-01 |
| NCT06612879 | A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk | COMPLETED | PHASE1 | 2024-10-18 | 2025-04-08 | 2025-03-11 |
| NCT06640933 | A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants | COMPLETED | PHASE1 | 2024-10-16 | 2025-02-07 | 2025-02-07 |
| NCT06574828 | A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants | COMPLETED | PHASE1 | 2024-08-29 | 2025-03-22 | 2025-03-22 |
| NCT06054893 | A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | RECRUITING | PHASE1 | 2024-07-01 | 2030-02-21 | 2030-02-21 |
| NCT06311786 | A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants | COMPLETED | PHASE1 | 2024-04-08 | 2024-05-11 | 2024-05-11 |
| NCT05764122 | A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well | WITHDRAWN | PHASE2 | 2024-03-29 | 2025-07-07 | 2025-07-07 |
| NCT06264440 | A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants | COMPLETED | PHASE1 | 2024-02-12 | 2024-06-18 | 2024-06-18 |
| NCT06262477 | A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants | COMPLETED | PHASE1 | 2024-01-02 | 2024-10-04 | 2024-09-25 |
| NCT06064929 | A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old | RECRUITING | PHASE1, PHASE2 | 2023-11-01 | 2026-06-01 | 2026-06-01 |
| NCT06044337 | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION | PHASE3 | 2023-10-03 | 2029-12-11 | 2029-06-26 |
| NCT05895552 | A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS) | TERMINATED | PHASE2 | 2023-07-28 | 2024-11-15 | 2024-11-15 |
| NCT05798520 | A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) | RECRUITING | PHASE2 | 2023-07-25 | 2027-09-07 | 2027-09-07 |
| NCT05927649 | A TQTc Study for Omaveloxolone | COMPLETED | PHASE1 | 2023-07-11 | 2023-09-01 | 2023-09-01 |
| NCT05928585 | A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers | COMPLETED | PHASE1 | 2023-07-06 | 2024-06-10 | 2024-06-10 |
| NCT05909644 | An Open-label DDI Study of Omaveloxolone in Healthy Subjects | COMPLETED | PHASE1 | 2023-07-05 | 2023-08-30 | 2023-08-30 |
| NCT05658484 | A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China | COMPLETED | PHASE4 | 2023-06-09 | 2025-04-12 | 2025-03-27 |
| NCT05655507 | Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD) | COMPLETED | PHASE1 | 2023-04-19 | 2024-10-18 | 2024-10-18 |
| NCT03070132 | 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | WITHDRAWN | PHASE3 | 2023-04-19 | 2026-08-21 | 2025-10-14 |
| NCT03637387 | 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | WITHDRAWN | PHASE3 | 2023-03-01 | 2026-09-29 | 2025-08-18 |
| NCT05532163 | A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | PHASE4 | 2023-01-23 | 2023-10-09 | 2023-10-09 |
| NCT05575011 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-10-10 | 2031-11-14 | 2031-11-14 |
| NCT05531565 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | RECRUITING | PHASE2, PHASE3 | 2022-09-13 | 2027-12-14 | 2026-10-20 |
| NCT05418673 | A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale | TERMINATED | PHASE3 | 2022-08-26 | 2023-07-27 | 2023-07-27 |
| NCT05399888 | A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-08-24 | 2029-01-08 | 2026-05-14 |
| NCT05352919 | An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION | PHASE3 | 2022-06-10 | 2030-03-29 | 2030-03-29 |
| NCT05310071 | A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease | TERMINATED | PHASE3 | 2022-06-02 | 2024-08-12 | 2024-08-12 |
| NCT05354414 | Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy | COMPLETED | NA | 2022-05-11 | 2024-07-12 | 2024-07-12 |
| NCT05265728 | A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis | TERMINATED | PHASE3 | 2022-04-26 | 2024-05-27 | 2024-01-18 |
| NCT05348785 | A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-04-19 | 2025-12-15 | 2025-12-01 |
| NCT05229562 | A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants | COMPLETED | PHASE1 | 2022-02-17 | 2022-09-07 | 2022-09-07 |
| NCT05109637 | A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders | COMPLETED | NA | 2022-02-10 | 2023-07-25 | 2023-07-10 |
| NCT05160558 | A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 | TERMINATED | PHASE1 | 2022-02-02 | 2023-07-25 | 2023-07-25 |
| NCT05216887 | A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers | COMPLETED | PHASE1 | 2022-02-01 | 2022-07-27 | 2022-07-27 |
| NCT05195008 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants | COMPLETED | PHASE1 | 2022-01-24 | 2023-07-10 | 2023-07-10 |
| NCT05067790 | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-01-21 | 2027-06-14 | 2027-06-14 |
| NCT05152485 | A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants | COMPLETED | PHASE1 | 2021-12-15 | 2022-01-31 | 2022-01-31 |
| NCT05127564 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants | COMPLETED | PHASE1 | 2021-12-03 | 2022-06-29 | 2022-06-09 |
| NCT05148481 | A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | COMPLETED | PHASE1 | 2021-11-23 | 2022-02-12 | 2022-01-30 |
| NCT05083923 | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) | COMPLETED | PHASE3 | 2021-11-18 | 2024-09-11 | 2024-09-11 |
| NCT05065970 | Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy | COMPLETED | PHASE2 | 2021-08-31 | 2024-05-06 | 2023-02-06 |
| NCT05119790 | A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects | COMPLETED | PHASE1 | 2021-08-27 | 2021-11-05 | 2021-11-05 |
| NCT05005338 | A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects | COMPLETED | PHASE1 | 2021-07-28 | 2021-09-23 | 2021-09-23 |
| NCT04961567 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | RECRUITING | PHASE3 | 2021-07-16 | 2027-03-16 | 2026-09-30 |
| NCT04079088 | Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) | WITHDRAWN | PHASE2 | 2021-06-30 | 2024-09-18 | 2024-09-18 |
| NCT04924140 | A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers | COMPLETED | PHASE1 | 2021-06-30 | 2021-10-01 | 2021-10-01 |
| NCT04895241 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | RECRUITING | PHASE3 | 2021-05-25 | 2027-03-16 | 2026-09-30 |
| NCT04856982 | A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-05-17 | 2027-08-07 | 2027-08-07 |
| NCT04729907 | A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-04-19 | 2026-07-31 | 2026-07-31 |
| NCT04702997 | A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN) | COMPLETED | PHASE2 | 2021-02-09 | 2021-11-23 | 2021-10-20 |
| NCT04733040 | Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) | COMPLETED | PHASE2 | 2021-01-20 | 2023-12-14 | 2023-12-14 |
| NCT04488133 | A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) | ACTIVE_NOT_RECRUITING | PHASE4 | 2021-01-04 | 2025-10-07 | 2025-10-07 |
| NCT04476030 | A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | COMPLETED | PHASE3 | 2020-11-09 | 2021-12-22 | 2021-10-25 |
| NCT04593121 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants | COMPLETED | PHASE1 | 2020-10-30 | 2024-03-05 | 2024-03-05 |
| NCT04571424 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants | COMPLETED | PHASE1 | 2020-10-14 | 2021-04-08 | 2021-04-08 |
| NCT04756700 | Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis | COMPLETED | NA | 2020-10-12 | 2022-07-26 | 2022-07-26 |
| NCT04106050 | Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy | WITHDRAWN | PHASE1 | 2020-09-30 | 2022-01-21 | 2022-01-21 |
| NCT04494256 | A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation | TERMINATED | PHASE1, PHASE2 | 2020-09-28 | 2024-08-13 | 2024-08-13 |
| NCT04564612 | Study of BIIB091 Formulations in Healthy Participants | COMPLETED | PHASE1 | 2020-09-28 | 2022-09-07 | 2022-09-07 |
| NCT04442503 | A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) | COMPLETED | PHASE3 | 2020-06-08 | 2022-04-12 | 2022-03-15 |
| NCT04442490 | A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD) | COMPLETED | PHASE3 | 2020-05-12 | 2021-04-21 | 2021-03-26 |
| NCT04288856 | Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS) | TERMINATED | PHASE1 | 2020-04-28 | 2022-05-03 | 2022-05-03 |
| NCT04089566 | Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | COMPLETED | PHASE3 | 2020-03-26 | 2024-05-30 | 2024-02-21 |
| NCT04241068 | A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 | TERMINATED | PHASE3 | 2020-03-02 | 2024-07-22 | 2024-07-22 |
| NCT04103333 | Angelman Syndrome (AS) Biomarker Study | COMPLETED | EARLY_PHASE1 | 2019-12-18 | 2022-01-02 | 2022-01-02 |
| NCT04068532 | A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants | COMPLETED | PHASE1 | 2019-11-15 | 2020-11-11 | 2020-11-11 |
| NCT03958877 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-10-18 | 2027-05-20 | 2027-05-20 |
| NCT04145440 | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | COMPLETED | PHASE1, PHASE2 | 2019-10-15 | 2022-08-02 | 2022-01-19 |
| NCT04079101 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | COMPLETED | PHASE1 | 2019-10-02 | 2019-12-27 | 2019-12-27 |
| NCT04007367 | A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder | TERMINATED | PHASE3 | 2019-08-06 | 2020-01-06 | 2020-01-06 |
| NCT04056689 | Study to Evaluate DNL151 in Subjects With Parkinson's Disease | COMPLETED | PHASE1 | 2019-07-23 | 2020-12-02 | 2020-12-02 |
| NCT03902002 | A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function | COMPLETED | PHASE1 | 2019-07-19 | 2020-01-27 | 2020-01-27 |
| NCT04008186 | A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone | COMPLETED | PHASE1 | 2019-06-14 | 2019-08-28 | 2019-08-18 |
| NCT03945279 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | COMPLETED | PHASE1 | 2019-05-30 | 2021-06-21 | 2021-06-21 |
| NCT03918447 | A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON | TERMINATED | PHASE3 | 2019-05-29 | 2023-08-08 | 2023-08-08 |
| NCT03943056 | A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants | COMPLETED | PHASE1 | 2019-05-13 | 2020-01-10 | 2020-01-10 |
| NCT03931590 | A Human AME Study for Omaveloxolone | COMPLETED | PHASE1 | 2019-04-11 | 2019-05-31 | 2019-05-31 |
| NCT03870763 | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | TERMINATED | PHASE3 | 2019-03-19 | 2022-07-21 | 2022-07-21 |
| NCT03716570 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease | TERMINATED | PHASE1 | 2019-03-12 | 2021-04-23 | 2021-04-23 |
| NCT03749447 | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) | TERMINATED | PHASE3 | 2019-03-08 | 2023-08-23 | 2023-08-23 |
| NCT03864614 | A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD) | COMPLETED | PHASE3 | 2019-02-27 | 2023-06-22 | 2023-06-22 |
| NCT03771664 | A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia | TERMINATED | PHASE3 | 2019-02-04 | 2020-01-17 | 2019-12-20 |
| NCT03764488 | A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults | COMPLETED | PHASE1 | 2018-12-20 | 2021-07-10 | 2021-06-10 |
| NCT03639987 | A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities | TERMINATED | PHASE2 | 2018-12-20 | 2019-07-30 | 2019-07-30 |
| NCT03689972 | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration | COMPLETED | PHASE3 | 2018-11-27 | 2023-07-24 | 2023-01-31 |
| NCT03672175 | A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder | COMPLETED | PHASE3 | 2018-11-19 | 2020-03-17 | 2019-09-24 |
| NCT03745820 | A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | COMPLETED | PHASE2 | 2018-11-15 | 2022-04-07 | 2022-03-23 |
| NCT03664453 | A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers | COMPLETED | PHASE1 | 2018-10-29 | 2018-11-20 | 2018-11-20 |
| NCT03573505 | An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis | TERMINATED | PHASE2 | 2018-09-24 | 2019-11-14 | 2019-11-14 |
| NCT03626012 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | COMPLETED | PHASE1 | 2018-09-10 | 2021-11-17 | 2021-11-17 |
| NCT03692910 | A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode | COMPLETED | PHASE2 | 2018-08-23 | 2019-05-21 | 2019-05-21 |
| NCT03579030 | Safety and PK/PD of RTA 1701 in Healthy Adults | COMPLETED | PHASE1 | 2018-06-20 | 2019-06-28 | 2019-06-28 |
| NCT03584165 | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa | ENROLLING_BY_INVITATION | PHASE3 | 2018-06-04 | 2026-06-04 | 2026-06-04 |
| NCT03339336 | Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy | TERMINATED | PHASE2 | 2018-05-31 | 2021-04-12 | 2021-04-12 |
| NCT03352557 | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | TERMINATED | PHASE2 | 2018-05-03 | 2021-08-30 | 2021-08-30 |
| NCT03454126 | Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants | COMPLETED | PHASE1 | 2018-03-29 | 2019-04-30 | 2019-04-30 |
| NCT03283371 | Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | COMPLETED | PHASE2 | 2018-03-20 | 2020-11-18 | 2020-01-11 |
| NCT03318523 | Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | TERMINATED | PHASE2 | 2018-01-10 | 2021-04-29 | 2020-10-26 |
| NCT03366337 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | COMPLETED | PHASE2 | 2017-12-26 | 2019-01-29 | 2019-01-02 |
| NCT03496012 | Efficacy and Safety of BIIB111 for the Treatment of Choroideremia | COMPLETED | PHASE3 | 2017-12-11 | 2020-12-01 | 2020-12-01 |
| NCT03507686 | A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 | COMPLETED | PHASE2 | 2017-11-29 | 2022-06-29 | 2022-06-29 |
| NCT03222973 | Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | TERMINATED | PHASE2 | 2017-11-15 | 2021-02-12 | 2021-02-12 |
| NCT03324685 | A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen | COMPLETED | PHASE1 | 2017-11-11 | 2018-03-15 | 2018-03-15 |
| NCT03264079 | Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults | COMPLETED | PHASE1 | 2017-10-16 | 2017-11-13 | 2017-11-13 |
| NCT03224793 | Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects. | COMPLETED | PHASE1 | 2017-10-04 | 2018-06-12 | 2018-06-12 |
| NCT03284931 | A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model | COMPLETED | PHASE1 | 2017-09-14 | 2017-12-18 | 2017-12-04 |
| NCT03385525 | Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 | COMPLETED | PHASE1 | 2017-09-12 | 2017-10-13 | 2017-10-13 |
| NCT03068468 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | TERMINATED | PHASE2 | 2017-06-01 | 2020-02-07 | 2019-09-06 |
| NCT03068130 | Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER | TERMINATED | PHASE3 | 2017-04-18 | 2020-09-30 | 2020-09-30 |
| NCT02881567 | Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab | TERMINATED | PHASE3 | 2017-04-18 | 2018-09-12 | 2018-09-12 |
| NCT02978781 | A Study to Evaluate SAGE-217 in Participants With Essential Tremor | COMPLETED | PHASE2 | 2017-03-24 | 2017-12-05 | 2017-11-22 |
| NCT03093324 | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 | COMPLETED | PHASE3 | 2017-03-15 | 2019-06-27 | 2019-06-27 |
| NCT03091569 | Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy | COMPLETED | PHASE4 | 2017-03-10 | 2018-01-27 | 2018-01-27 |
| NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | COMPLETED | PHASE3 | 2017-03-08 | 2024-08-12 | 2024-08-12 |
| NCT03116113 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 | COMPLETED | PHASE1, PHASE2 | 2017-03-08 | 2020-11-18 | 2020-11-18 |
| NCT03019185 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL | COMPLETED | PHASE2, PHASE3 | 2017-03-02 | 2020-10-30 | 2020-10-06 |
| NCT03056729 | Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease | COMPLETED | PHASE1 | 2017-02-17 | 2020-03-03 | 2020-03-03 |
| NCT02957617 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 | TERMINATED | PHASE2 | 2017-02-10 | 2019-02-07 | 2019-02-07 |
| NCT03177083 | Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy | COMPLETED | PHASE4 | 2017-01-30 | 2020-10-26 | 2020-10-26 |
| NCT02978326 | A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression | COMPLETED | PHASE3 | 2017-01-04 | 2018-12-11 | 2018-11-15 |
| NCT02666963 | A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults | COMPLETED | PHASE1 | 2017-01-01 | 2017-07-23 | 2017-07-23 |
| NCT03000530 | A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder | COMPLETED | PHASE2 | 2016-12-07 | 2017-11-08 | 2017-10-04 |
| NCT02951221 | New Formulation and Food Effect Study of BIIB074 | COMPLETED | PHASE1 | 2016-12 | 2017-02 | 2017-02 |
| NCT03000569 | A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease | COMPLETED | PHASE2 | 2016-11-30 | 2017-09-11 | 2017-09-11 |
| NCT02935608 | Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy | COMPLETED | PHASE2 | 2016-10-31 | 2018-08-06 | 2018-08-06 |
| NCT02847598 | Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE2 | 2016-10-20 | 2019-11-18 | 2019-08-28 |
| NCT02657356 | Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST | TERMINATED | PHASE3 | 2016-10-04 | 2020-05-07 | 2020-05-07 |
| NCT02917187 | A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia | COMPLETED | PHASE2 | 2016-09-09 | 2017-01-05 | 2016-12-27 |
| NCT02855411 | A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | PHASE2 | 2016-08-29 | 2016-09-26 | 2016-09-26 |
| NCT02831517 | PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants | COMPLETED | PHASE1 | 2016-08 | 2017-02 | 2017-02 |
| NCT02829541 | A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants | COMPLETED | PHASE1 | 2016-08 | 2016-12 | 2016-12 |
| NCT02730455 | Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke | COMPLETED | PHASE2 | 2016-07-18 | 2017-11-20 | 2017-11-20 |
| NCT02833142 | Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes | COMPLETED | PHASE1 | 2016-07 | 2016-11 | 2016-11 |
| NCT02782975 | Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants | COMPLETED | PHASE1 | 2016-05 | 2016-11 | 2016-11 |
| NCT02428218 | Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | PHASE3 | 2016-05 | 2027-01 | 2027-01 |
| NCT02751905 | Absorption, Metabolism, and Excretion Study of BIIB074 | COMPLETED | PHASE1 | 2016-04 | 2016-05 | 2016-05 |
| NCT02691702 | Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers | COMPLETED | PHASE1 | 2016-03-28 | 2017-01-12 | 2017-01-12 |
| NCT02657915 | Long-Term Assessment of Remyelinating Therapy | COMPLETED | PHASE2 | 2016-03-10 | 2017-01-23 | 2017-01-23 |
| NCT02658916 | Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 | TERMINATED | PHASE1 | 2016-02-22 | 2020-03-31 | 2020-03-31 |
| NCT02555215 | Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE3 | 2016-02-22 | 2018-09-24 | 2018-09-24 |
| NCT02587065 | Plegridy Satisfaction Study in Participants | COMPLETED | PHASE4 | 2016-02-03 | 2017-12-21 | 2017-10-02 |
| NCT02641041 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants | COMPLETED | PHASE1 | 2016-02 | 2016-09 | 2016-09 |
| NCT02698267 | Effect of Itraconazole on the Pharmacokinetics of BIIB074 | COMPLETED | PHASE1 | 2016-02 | 2016-04 | 2016-04 |
| NCT02568111 | Brimonidine Tartrate for the Treatment of Injection Related Erythema | WITHDRAWN | PHASE4 | 2016-02 | 2016-08 | 2016-08 |
| NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | PHASE3 | 2016-01-20 | 2021-07-16 | 2021-07-16 |
| NCT02634307 | A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 | COMPLETED | PHASE3 | 2015-12-10 | 2021-11-11 | 2021-06-01 |
| NCT02471560 | Tecfidera and the Gut Microbiota | COMPLETED | PHASE4 | 2015-11-06 | 2017-06-12 | 2017-06-12 |
| NCT02594124 | A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies | COMPLETED | PHASE3 | 2015-11-04 | 2023-08-21 | 2023-08-21 |
| NCT02460094 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | COMPLETED | PHASE1 | 2015-10-02 | 2016-10-19 | 2016-10-19 |
| NCT02410200 | Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS | COMPLETED | PHASE2 | 2015-09-30 | 2016-09-23 | 2016-09-23 |
| NCT02555085 | Single Ascending Doses of BIIB063 in Healthy Volunteers | TERMINATED | PHASE1 | 2015-09-30 | 2016-06-01 | 2016-06-01 |
| NCT02484547 | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | TERMINATED | PHASE3 | 2015-09-15 | 2019-08-05 | 2019-08-05 |
| NCT02462759 | A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). | TERMINATED | PHASE2 | 2015-08-19 | 2018-09-24 | 2018-09-24 |
| NCT02477800 | 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | TERMINATED | PHASE3 | 2015-08-13 | 2019-08-08 | 2019-08-08 |
| NCT02525874 | Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). | COMPLETED | PHASE3 | 2015-08-11 | 2018-04-23 | 2017-04-24 |
| NCT02459886 | Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease | COMPLETED | PHASE1 | 2015-07-01 | 2017-11-20 | 2017-11-20 |
| NCT02472938 | Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis | WITHDRAWN | PHASE4 | 2015-07 | 2020-07 | 2019-07 |
| NCT02521545 | Single-Dose Study of a New Formulation of BIIB061 | COMPLETED | PHASE1 | 2015-07 | 2015-08 | 2015-08 |
| NCT02434718 | Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease | COMPLETED | PHASE1 | 2015-06-24 | 2016-12-09 | 2016-12-09 |
| NCT02090348 | Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate | WITHDRAWN | PHASE4 | 2015-06 | 2017-10 | 2017-10 |
| NCT02443740 | Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749) | COMPLETED | PHASE1 | 2015-05-31 | 2015-10-31 | 2015-10-31 |
| NCT02386553 | A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | COMPLETED | PHASE2 | 2015-05-18 | 2024-12-17 | 2024-12-17 |
| NCT02255422 | RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR | COMPLETED | PHASE2 | 2015-05-05 | 2017-11-30 | 2017-11-02 |
| NCT02430532 | BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis | TERMINATED | PHASE3 | 2015-05 | 2016-01 | 2016-01 |
| NCT02551497 | Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects | COMPLETED | PHASE1 | 2015-04-30 | 2016-08-26 | 2016-08-16 |
| NCT02428231 | Tecfidera Slow-Titration Study | TERMINATED | PHASE3 | 2015-04 | 2016-01 | 2015-12 |
| NCT02410278 | Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera | COMPLETED | PHASE4 | 2015-03-12 | 2017-04-27 | 2017-02-16 |
| NCT02097849 | Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. | COMPLETED | PHASE2 | 2015-02-28 | 2016-05-02 | 2016-05-02 |
| NCT02343159 | Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients. | TERMINATED | PHASE4 | 2015-02-28 | 2016-04-15 | 2016-04-15 |
| NCT02341482 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects | COMPLETED | PHASE1 | 2015-02-05 | 2015-03-31 | 2015-03-31 |
| NCT02359344 | PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers | COMPLETED | PHASE1 | 2015-02-03 | 2015-04-20 | 2015-04-20 |
| NCT02255435 | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia | ACTIVE_NOT_RECRUITING | PHASE2 | 2015-01-31 | 2025-11-28 | 2019-10-31 |
| NCT02332798 | Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia | COMPLETED | PHASE1 | 2015-01-06 | 2015-04-15 | 2015-04-15 |
| NCT02294851 | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects | COMPLETED | PHASE1 | 2014-12-31 | 2016-04-30 | 2016-04-30 |
| NCT02142192 | Natalizumab Subcutaneous Immunogenicity and Safety Study | TERMINATED | PHASE2 | 2014-12-01 | 2015-06-04 | 2015-06-04 |
| NCT02342704 | Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants | TERMINATED | PHASE4 | 2014-11-30 | 2016-05-18 | 2016-05-18 |
| NCT02292537 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) | COMPLETED | PHASE3 | 2014-11-24 | 2017-02-20 | 2017-02-20 |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | COMPLETED | PHASE1, PHASE2 | 2014-10-31 | 2018-07-23 | 2018-05-09 |
| NCT02269930 | Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers | COMPLETED | PHASE1 | 2014-10 | 2014-12 | 2014-12 |
| NCT02234869 | Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy | WITHDRAWN | PHASE4 | 2014-10 | 2018-03 | 2017-02 |
| NCT02241785 | Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies | TERMINATED | PHASE4 | 2014-09-30 | 2016-05-02 | 2016-05-02 |
| NCT02228395 | Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers | COMPLETED | PHASE1 | 2014-09-22 | 2014-11-13 | 2014-11-13 |
| NCT02219932 | Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis | COMPLETED | PHASE3 | 2014-09 | 2016-02 | 2016-02 |
| NCT02283853 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE3 | 2014-08-28 | 2025-07-08 | 2025-07-08 |
| NCT02193074 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy | TERMINATED | PHASE3 | 2014-08-19 | 2016-11-21 | 2016-11-21 |
| NCT02228707 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2014-08 | 2016-05 | 2016-05 |
| NCT02201849 | A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults | COMPLETED | PHASE1 | 2014-07 | 2014-12 | 2014-12 |
| NCT02142959 | RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE | COMPLETED | PHASE2 | 2014-06-30 | 2015-04-30 | 2015-04-30 |
| NCT02125604 | Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany | COMPLETED | PHASE4 | 2014-06 | 2016-03 | 2016-02 |
| NCT02171208 | A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers | COMPLETED | PHASE1 | 2014-06 | 2014-07 | 2014-07 |
| NCT02036970 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | COMPLETED | PHASE2 | 2014-05-31 | 2018-05-16 | 2018-01-19 |
| NCT02128113 | RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD | COMPLETED | PHASE2 | 2014-05-31 | 2015-04-30 | 2015-02-28 |
| NCT02090413 | Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE4 | 2014-05 | 2015-11 | 2015-02 |
| NCT02106897 | Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus | COMPLETED | PHASE1 | 2014-04-30 | 2016-05-24 | 2016-05-24 |
| NCT02579681 | Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 | COMPLETED | PHASE3 | 2014-04-30 | 2016-12-21 | 2016-12-21 |
| NCT02065375 | RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery | COMPLETED | PHASE2 | 2014-02-28 | 2014-09-30 | 2014-09-30 |
| NCT02052791 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246) | COMPLETED | PHASE1 | 2014-01-31 | 2017-01-31 | 2017-01-31 |
| NCT01955707 | Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke | COMPLETED | PHASE2 | 2014-01 | 2015-04 | 2015-02 |
| NCT02029729 | RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | COMPLETED | PHASE1 | 2013-12-31 | 2015-10-01 | 2015-10-01 |
| NCT02029716 | RTA 408 Lotion in Healthy Volunteers | COMPLETED | PHASE1 | 2013-12-31 | 2014-04-01 | 2014-04-01 |
| NCT01978652 | Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants. | COMPLETED | PHASE1 | 2013-12 | 2014-02 | 2014-02 |
| NCT02071121 | Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect | COMPLETED | PHASE1 | 2013-12 | 2014-09 | 2014-09 |
| NCT01939002 | Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) | COMPLETED | PHASE3 | 2013-11 | 2015-11 | 2015-10 |
| NCT01930890 | BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis | TERMINATED | PHASE2 | 2013-11 | 2016-01 | 2016-01 |
| NCT01930708 | A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes | COMPLETED | PHASE4 | 2013-10-31 | 2020-01-09 | 2016-03-31 |
| NCT01943513 | A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers | COMPLETED | PHASE1 | 2013-10 | 2014-05 | 2014-01 |
| NCT01929746 | Daclizumab Japanese PK Study | COMPLETED | PHASE1 | 2013-10 | 2014-03 | 2014-03 |
| NCT01917019 | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis | COMPLETED | PHASE3 | 2013-08 | 2017-03 | 2015-10 |
| NCT01864148 | Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex | COMPLETED | PHASE2 | 2013-08 | 2016-03 | 2015-12 |
| NCT01924832 | BG00012 Regional Absorption Study | COMPLETED | PHASE1 | 2013-08 | 2014-04 | 2014-04 |
| NCT01915901 | PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily | COMPLETED | PHASE1 | 2013-08 | 2013-12 | 2013-12 |
| NCT01884935 | PK and PD Study of Natalizumab in Pediatric Subjects With RRMS | COMPLETED | PHASE1 | 2013-07 | 2014-09 | 2014-09 |
| NCT01873404 | BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy | COMPLETED | PHASE2 | 2013-06 | 2015-03 | 2015-03 |
| NCT01839656 | A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA) | COMPLETED | PHASE2 | 2013-05-08 | 2017-08-21 | 2017-08-21 |
| NCT01873417 | Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States | COMPLETED | PHASE4 | 2013-05 | 2013-11 | 2013-11 |
| NCT01842126 | Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin) | COMPLETED | PHASE1 | 2013-04 | 2014-08 | 2014-08 |
| NCT01838668 | An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE3 | 2013-03-28 | 2018-09-04 | 2015-06-16 |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | TERMINATED | PHASE3 | 2013-02-15 | 2018-09-24 | 2018-09-24 |
| NCT01780246 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701) | COMPLETED | PHASE1 | 2013-01-31 | 2014-02-28 | 2014-02-28 |
| NCT01749098 | A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers | COMPLETED | PHASE1 | 2012-12 | 2014-02 | 2014-02 |
| NCT01721161 | BIIB033 In Acute Optic Neuritis (AON) | COMPLETED | PHASE2 | 2012-12 | 2014-10 | 2014-10 |
| NCT01703988 | An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy | COMPLETED | PHASE1, PHASE2 | 2012-10-31 | 2015-01-31 | 2015-01-31 |
| NCT01677572 | Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease | TERMINATED | PHASE1 | 2012-10-05 | 2019-07-31 | 2019-07-31 |
| NCT01655186 | A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus | WITHDRAWN | PHASE2 | 2012-09-30 | 2012-10-31 | 2012-10-31 |
| NCT01689116 | Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers | COMPLETED | PHASE1 | 2012-08-31 | 2012-11-30 | 2012-11-30 |
| NCT01597297 | Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. | COMPLETED | PHASE2 | 2012-08 | 2013-08 | 2013-08 |
| NCT01652937 | BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs | WITHDRAWN | PHASE2 | 2012-08 | 2014-03 | 2014-02 |
| NCT01576887 | A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis | WITHDRAWN | PHASE2 | 2012-07-31 | 2012-10-31 | 2012-10-31 |
| NCT01371305 | STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | PHASE2 | 2012-07-16 | 2017-03-31 | 2017-03-31 |
| NCT01646840 | Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation | COMPLETED | PHASE1 | 2012-07 | 2012-09 | 2012-09 |
| NCT01499355 | BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis | TERMINATED | PHASE2 | 2012-07 | 2015-12 | 2015-12 |
| NCT01632449 | Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers. | COMPLETED | PHASE1 | 2012-07 | 2012-09 | 2012-09 |
| NCT01598363 | An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers | COMPLETED | PHASE1 | 2012-06-30 | 2012-07-31 | 2012-07-31 |
| NCT01610310 | Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers | COMPLETED | PHASE1 | 2012-06 | 2012-10 | 2012-10 |
| NCT02142205 | Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE4 | 2012-05 | 2013-12 | 2013-12 |
| NCT01551446 | Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes | WITHDRAWN | PHASE1 | 2012-04-30 | 2012-11-30 | 2012-11-30 |
| NCT01563562 | Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function | COMPLETED | PHASE1 | 2012-04-30 | 2012-11-30 | 2012-11-30 |
| NCT01549769 | Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes | TERMINATED | PHASE1 | 2012-04-30 | 2013-10-31 | 2012-11-30 |
| NCT01568112 | Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate | COMPLETED | PHASE3 | 2012-04 | 2012-10 | 2012-10 |
| NCT01540630 | A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia | COMPLETED | PHASE2 | 2012-03-31 | 2014-06-30 | 2014-03-31 |
| NCT01480076 | Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis | COMPLETED | PHASE4 | 2012-02 | 2013-08 | 2013-07 |
| NCT01500798 | A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes | TERMINATED | PHASE1 | 2012-01-31 | 2013-10-01 | 2012-11-01 |
| NCT01500408 | Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers | COMPLETED | PHASE1 | 2012-01 | 2012-04 | 2012-04 |
| NCT01453426 | Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers | COMPLETED | PHASE1 | 2012-01 | 2012-04 | 2012-04 |
| NCT01503866 | A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects | COMPLETED | PHASE1 | 2011-12-01 | 2011-12-31 | 2011-12-31 |
| NCT01518920 | A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss | COMPLETED | PHASE1 | 2011-12 | 2013-02 | 2013-02 |
| NCT01494701 | An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) | COMPLETED | PHASE1 | 2011-11-30 | 2013-01-31 | 2013-01-31 |
| NCT01518894 | A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia | COMPLETED | PHASE1 | 2011-11 | 2012-03 | 2012-03 |
| NCT01462318 | An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | COMPLETED | PHASE3 | 2011-11 | 2016-01 | 2016-01 |
| NCT01461161 | A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl | COMPLETED | PHASE1 | 2011-10-31 | 2011-12-31 | 2011-12-31 |
| NCT01416181 | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | TERMINATED | PHASE3 | 2011-09-13 | 2016-04-13 | 2015-07-28 |
| NCT01407406 | Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers | COMPLETED | PHASE1 | 2011-09 | 2012-02 | 2012-02 |
| NCT01405820 | Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) | COMPLETED | PHASE2 | 2011-08 | 2014-10 | 2014-04 |
| NCT01416207 | A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects | COMPLETED | PHASE1 | 2011-08 | 2011-10 | 2011-10 |
| NCT01420458 | Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012 | COMPLETED | PHASE1 | 2011-08 | 2011-09 | 2011-09 |
| NCT01405833 | Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica. | COMPLETED | PHASE1 | 2011-07 | 2012-09 | 2012-09 |
| NCT01351675 | Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes | TERMINATED | PHASE3 | 2011-06-30 | 2012-12-31 | 2012-10-31 |
| NCT01365338 | A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects | COMPLETED | PHASE1 | 2011-06-24 | 2012-12-14 | 2012-12-14 |
| NCT01511510 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers | COMPLETED | PHASE1 | 2011-06 | 2011-11 | 2011-11 |
| NCT01397539 | Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease | COMPLETED | PHASE1 | 2011-06 | 2013-08 | 2013-08 |
| NCT01561027 | Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | COMPLETED | PHASE2 | 2011-04-30 | 2012-08-31 | 2012-06-30 |
| NCT01332019 | Long-Term Safety and Efficacy Study of Peginterferon Beta-1a | COMPLETED | PHASE3 | 2011-04 | 2015-10 | 2015-10 |
| NCT01556685 | MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia | COMPLETED | PHASE4 | 2011-03 | | 2011-10 |
| NCT01313364 | A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle | TERMINATED | PHASE1 | 2011-03 | 2011-04 | 2011-04 |
| NCT01281111 | Alternate Dosing Regimens of BG00012 in Healthy Volunteers | COMPLETED | PHASE1 | 2011-02-01 | 2011-03-18 | 2011-03-18 |
| NCT01235221 | Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. | COMPLETED | PHASE3 | 2010-12 | 2012-06 | 2012-06 |
| NCT01238679 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers | TERMINATED | PHASE1 | 2010-11-24 | 2011-05-03 | 2011-05-03 |
| NCT01440101 | Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE2, PHASE3 | 2010-11 | 2012-08 | 2012-08 |
| NCT01244139 | Safety Study of BIIB033 in Subjects With Multiple Sclerosis | COMPLETED | PHASE1 | 2010-10 | 2012-04 | 2012-04 |
| NCT01416155 | Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE2 | 2010-10 | 2014-12 | 2014-12 |
| NCT01215084 | A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers | COMPLETED | PHASE1 | 2010-10 | 2010-11 | 2010-11 |
| NCT01211665 | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | TERMINATED | PHASE4 | 2010-09 | 2012-02 | 2012-02 |
| NCT01181089 | Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) | WITHDRAWN | PHASE1, PHASE2 | 2010-09 | | |
| NCT01159483 | First-in-Human Study of PF-04958242 in Healthy Volunteers | COMPLETED | PHASE1 | 2010-07-15 | 2010-10-16 | 2010-10-16 |
| NCT01156311 | BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis | COMPLETED | PHASE2 | 2010-06 | 2012-03 | 2012-03 |
| NCT01119677 | A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers | COMPLETED | PHASE1 | 2010-05-05 | 2010-10-23 | 2010-10-23 |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 | 2010-05 | 2014-07 | 2014-03 |
| NCT01119781 | A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers | COMPLETED | PHASE1 | 2010-05 | 2011-08 | 2011-08 |
| NCT01181115 | Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) | COMPLETED | PHASE3 | 2010-04 | 2011-10 | 2011-10 |
| NCT01051349 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis | COMPLETED | PHASE2 | 2010-03-31 | 2016-08-25 | 2016-08-25 |
| NCT01058005 | Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis | TERMINATED | PHASE3 | 2010-03 | 2012-04 | 2012-04 |
| NCT01071083 | Treatment Interruption of Natalizumab | COMPLETED | PHASE2 | 2010-03 | 2011-11 | 2011-11 |
| NCT01053936 | Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | COMPLETED | PHASE2 | 2010-01-31 | 2011-02-28 | 2010-12-31 |
| NCT01132703 | Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers | COMPLETED | PHASE1 | 2010-01-07 | 2010-05-07 | 2010-05-07 |
| NCT01052506 | BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects | COMPLETED | PHASE1 | 2010-01 | 2011-10 | 2011-10 |
| NCT01035515 | BIIB014 Cardiovascular Monitoring Study | COMPLETED | PHASE1 | 2009-12 | 2010-04 | 2010-04 |
| NCT01017666 | BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam | COMPLETED | PHASE1 | 2009-11-01 | 2010-06-02 | 2010-06-02 |
| NCT01004081 | Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | COMPLETED | PHASE2 | 2009-11 | 2011-10 | 2011-10 |
| NCT01017198 | Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors | COMPLETED | PHASE1 | 2009-11 | 2011-01 | 2010-08 |
| NCT00970580 | A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | COMPLETED | PHASE1 | 2009-10 | 2011-09 | 2011-09 |
| NCT01069913 | Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient | COMPLETED | PHASE1 | 2009-10 | 2010-01 | 2009-10 |
| NCT00871780 | A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients | COMPLETED | PHASE4 | 2009-08 | 2012-07 | 2012-07 |
| NCT00961766 | Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants | COMPLETED | PHASE1 | 2009-08 | 2012-02 | 2012-02 |
| NCT00956436 | Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | COMPLETED | PHASE1 | 2009-08 | 2011-04 | 2011-04 |
| NCT00955396 | Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure | COMPLETED | PHASE1 | 2009-07-31 | 2009-12-31 | 2009-12-31 |
| NCT00964288 | Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects | TERMINATED | PHASE1 | 2009-07-31 | 2009-11-30 | 2009-11-30 |
| NCT00906399 | Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis | COMPLETED | PHASE3 | 2009-06 | 2013-10 | 2012-10 |
| NCT00811889 | Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | COMPLETED | PHASE2 | 2009-04-30 | 2010-12-31 | 2010-05-31 |
| NCT00858156 | BG9928 in Subjects With Hepatic Impairment | COMPLETED | PHASE1 | 2009-04 | 2009-08 | 2009-08 |
| NCT00837785 | A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS | COMPLETED | PHASE1 | 2009-02-28 | 2009-10-31 | 2009-10-31 |
| NCT00835770 | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | COMPLETED | PHASE3 | 2009-02-03 | 2019-11-08 | 2019-11-08 |
| NCT00745316 | Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency | TERMINATED | PHASE2 | 2009-02 | 2010-01 | 2010-01 |
| NCT00870740 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE2 | 2009-02 | 2012-10 | 2012-05 |
| NCT00746941 | Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | TERMINATED | PHASE1, PHASE2 | 2009-01 | 2010-11 | 2010-11 |
| NCT00828204 | Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects | COMPLETED | PHASE3 | 2009-01 | 2010-10 | 2010-07 |
| NCT00810836 | Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis | COMPLETED | PHASE2 | 2008-12 | 2010-03 | 2010-02 |
| NCT00801125 | Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy | WITHDRAWN | PHASE4 | 2008-12 | | 2010-05 |
| NCT00771043 | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a | WITHDRAWN | PHASE4 | 2008-11-01 | 2010-06-01 | 2009-08-01 |
| NCT00744679 | A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | COMPLETED | PHASE4 | 2008-11 | 2008-12 | 2008-12 |
| NCT00784836 | Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients | TERMINATED | PHASE3 | 2008-10 | 2009-02 | 2009-02 |
| NCT00771329 | BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis | COMPLETED | PHASE1 | 2008-10 | 2011-04 | 2011-04 |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | TERMINATED | PHASE1, PHASE2 | 2008-09 | 2009-12 | 2009-12 |
| NCT00651443 | Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | TERMINATED | PHASE1 | 2008-08 | 2010-12 | 2010-11 |
| NCT00709865 | Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency | COMPLETED | PHASE3 | 2008-07-31 | 2009-12-31 | 2009-10-30 |
| NCT00725933 | Administration of BIIB028 to Subjects With Solid Tumors | COMPLETED | PHASE1 | 2008-06 | 2011-10 | 2011-10 |
| NCT00674947 | A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors | COMPLETED | PHASE1 | 2008-06 | 2011-06 | 2011-06 |
| NCT00908154 | Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. | COMPLETED | PHASE1 | 2008-05-31 | 2008-12-31 | 2008-12-31 |
| NCT00616434 | A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis | COMPLETED | PHASE2 | 2008-05 | 2010-03 | 2010-03 |
| NCT00664027 | Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy | COMPLETED | PHASE2 | 2008-04-30 | 2009-05-31 | 2009-05-31 |
| NCT02125578 | A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers | COMPLETED | PHASE1 | 2008-03 | 2008-05 | 2008-05 |
| NCT00618735 | Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2008-02 | 2010-12 | 2010-07 |
| NCT00390221 | Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE2 | 2008-02 | 2011-08 | 2011-05 |
| NCT00801060 | Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | TERMINATED | PHASE2 | 2008-02 | 2010-09 | 2010-06 |
| NCT00618319 | An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) | COMPLETED | PHASE2 | 2008-02 | 2010-04 | 2010-04 |
| NCT00555724 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | COMPLETED | PHASE1 | 2008-01 | 2010-07 | 2010-04 |
| NCT00536120 | The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis | COMPLETED | PHASE4 | 2008-01 | 2009-12 | 2009-11 |
| NCT00412412 | CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study | COMPLETED | PHASE1 | 2007-12 | 2011-04 | 2011-04 |
| NCT00664573 | 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants | TERMINATED | PHASE2 | 2007-11 | 2008-10 | 2008-10 |
| NCT00384150 | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | TERMINATED | PHASE3 | 2007-11 | 2010-01 | 2010-01 |
| NCT00538343 | RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases | TERMINATED | PHASE2 | 2007-10-31 | 2009-01-01 | 2008-12-01 |
| NCT00559702 | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | COMPLETED | PHASE1 | 2007-10 | 2011-11 | 2011-11 |
| NCT00529113 | Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer | TERMINATED | PHASE1 | 2007-09-30 | 2009-11-01 | 2009-11-01 |
| NCT00531193 | Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers | COMPLETED | PHASE1 | 2007-09 | 2008-04 | 2008-04 |
| NCT00523328 | BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861) | TERMINATED | PHASE2 | 2007-08 | 2008-10 | 2008-10 |
| NCT00442780 | Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease | COMPLETED | PHASE2 | 2007-08 | 2008-12 | 2008-12 |
| NCT00664716 | Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants | COMPLETED | PHASE2 | 2007-07 | 2008-10 | 2008-10 |
| NCT00451451 | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 | 2007-06 | 2011-08 | 2011-08 |
| NCT00574041 | How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose | TERMINATED | PHASE4 | 2007-06 | 2008-02 | 2008-02 |
| NCT00488566 | GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers | COMPLETED | PHASE1 | 2007-05-31 | 2008-05-31 | 2008-05-31 |
| NCT00550849 | Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction | TERMINATED | PHASE1, PHASE2 | 2007-04-30 | 2007-11-30 | 2007-11-30 |
| NCT00438607 | Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease | COMPLETED | PHASE2 | 2007-04 | 2009-04 | 2009-04 |
| NCT00458861 | BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis | TERMINATED | PHASE2 | 2007-03 | 2008-10 | 2008-10 |
| NCT00420212 | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 | 2007-01 | 2011-02 | 2011-02 |
| NCT00424788 | A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) | COMPLETED | EARLY_PHASE1 | 2007-01 | 2007-10 | 2007-10 |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | TERMINATED | PHASE2 | 2006-11 | 2010-12 | 2010-07 |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis | TERMINATED | PHASE1 | 2006-10-31 | | 2008-12-01 |
| NCT00516893 | Natalizumab High Titer Immunogenicity and Safety | COMPLETED | PHASE2 | 2006-10 | 2007-12 | 2007-10 |
| NCT00363636 | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) | TERMINATED | PHASE3 | 2006-09 | 2010-04 | 2010-01 |
| NCT00298272 | Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis | TERMINATED | PHASE2 | 2006-05 | 2011-07 | 2009-04 |
| NCT00529438 | RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | COMPLETED | PHASE1 | 2006-04-30 | 2008-12-01 | 2008-12-01 |
| NCT00306592 | Natalizumab Re-Initiation of Dosing | COMPLETED | PHASE3 | 2006-03 | 2008-02 | 2007-12 |
| NCT00297232 | Natalizumab (Tysabri) Re-Initiation of Dosing | TERMINATED | PHASE3 | 2006-03 | 2014-04 | 2014-04 |
| NCT00492765 | Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE4 | 2006-02 | 2010-04 | 2010-04 |
| NCT00345189 | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | COMPLETED | PHASE1 | 2006-02 | 2009-04 | 2008-07 |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | TERMINATED | PHASE1 | 2006-02 | 2008-09 | 2008-07 |
| NCT00526812 | A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas | COMPLETED | PHASE1 | 2005-11-30 | | 2008-12-01 |
| NCT00292422 | Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis | COMPLETED | PHASE2 | 2005-11 | 2007-05 | 2007-05 |
| NCT00915577 | Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe | COMPLETED | PHASE3 | 2005-08 | 2006-04 | 2006-04 |
| NCT00319930 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | TERMINATED | PHASE1 | 2005-05 | 2007-05 | |
| NCT00107861 | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases | COMPLETED | PHASE1, PHASE2 | 2005-05 | 2006-09 | |
| NCT00105170 | Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors | TERMINATED | PHASE1 | 2005-01 | 2006-08 | 2006-08 |
| NCT00102024 | Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma | TERMINATED | PHASE1, PHASE2 | 2005-01 | 2006-01 | 2006-01 |
| NCT00168701 | Efficacy and Safety of BG00012 in MS | COMPLETED | PHASE2 | 2004-10-01 | 2006-03-31 | 2006-03-31 |
| NCT00831649 | A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 | TERMINATED | PHASE2 | 2004-09 | | 2005-02 |
| NCT00083759 | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | TERMINATED | PHASE2 | 2004-05 | | 2005-02 |
| NCT00493077 | Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy | COMPLETED | PHASE4 | 2004-05 | 2006-05 | 2006-05 |
| NCT00078611 | A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE3 | 2004-03 | 2005-03 | 2005-03 |
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE1, PHASE2 | 2004-03 | 2010-03 | 2010-01 |
| NCT00099489 | Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | COMPLETED | PHASE2 | 2004-02 | 2006-02 | 2006-02 |
| NCT00276172 | Open-Label Natalizumab Safety Extension Study | COMPLETED | PHASE3 | 2003-12 | 2006-01 | 2005-10 |
| NCT00493116 | Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta | COMPLETED | PHASE4 | 2003-10 | 2009-12 | 2009-12 |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | COMPLETED | PHASE4 | 2003-10 | 2007-11 | 2007-06 |
| NCT00913250 | A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers | COMPLETED | PHASE1 | 2003-08 | 2003-10 | |
| NCT00168727 | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | COMPLETED | PHASE4 | 2003-06-01 | 2005-10-31 | |
| NCT00097760 | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE2 | 2003-06 | 2004-03 | 2004-03 |
| NCT00112034 | AVONEX® Combination Trial - "ACT" | COMPLETED | PHASE4 | 2003-06 | 2007-05 | 2006-06 |
| NCT00492466 | Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies | COMPLETED | PHASE4 | 2003-03 | 2006-08 | 2006-08 |
| NCT00057343 | Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma | TERMINATED | PHASE3 | 2003-03 | | |
| NCT00168766 | Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS | COMPLETED | PHASE4 | 2003-01 | 2008-11 | 2008-11 |
| NCT00912860 | Immunogenicity and Safety Study of Serum-Free Avonex | COMPLETED | PHASE2 | 2003-01 | 2005-01 | 2004-12 |
| NCT00233662 | Safety and Tolerability of Repeat Courses of IM Alefacept | COMPLETED | PHASE3 | 2002-12-01 | 2005-12-01 | |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | COMPLETED | PHASE1, PHASE2 | 2002-11 | 2010-11 | 2004-03 |
| NCT00913666 | Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers | COMPLETED | PHASE4 | 2002-11 | 2004-11 | |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE1 | 2002-09 | 2010-03 | 2004-04 |
| NCT00280956 | Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease | COMPLETED | PHASE4 | 2002-07 | 2004-09 | 2004-09 |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | COMPLETED | PHASE1 | 2002-04-02 | 2003-10-10 | |
| NCT00055536 | Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease | COMPLETED | PHASE2 | 2002-04 | 2003-07 | 2003-07 |
| NCT00055367 | Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease | COMPLETED | PHASE2 | 2002-04 | 2004-05 | 2004-05 |
| NCT00032786 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | COMPLETED | PHASE3 | 2002-03 | 2004-03 | 2004-03 |
| NCT00575068 | Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma | COMPLETED | PHASE1, PHASE2 | 2002-01 | 2010-11 | 2002-09 |
| NCT00030966 | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | COMPLETED | PHASE3 | 2002-01 | 2005-12 | 2005-04 |
| NCT00032799 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | COMPLETED | PHASE3 | 2001-12 | 2003-09 | 2003-09 |
| NCT00027300 | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | COMPLETED | PHASE3 | 2001-11 | 2005-01 | 2004-11 |
| NCT00534261 | Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? | COMPLETED | PHASE4 | 1999-11 | 2004-02 | |
| NCT00915460 | Open-Label Safety Extension Study of Avonex | COMPLETED | PHASE4 | 1999-09 | 2003-07 | 2003-06 |
| NCT00168740 | Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | COMPLETED | PHASE3 | 1995-04 | | |
| NCT00535314 | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | WITHDRAWN | PHASE2 | | | |
| NCT00451815 | BIIB014 Phase 2a Monotherapy | WITHDRAWN | PHASE2 | | | |